AR-V7 and prostate cancer: The watershed for treatment selection?
- 1 February 2016
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 43, 27-35
Abstract
No abstract availableKeywords
Funding Information
- Italian Association for Cancer Research (AIRC-IG 11930)
This publication has 82 references indexed in Scilit:
- Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer CellsPLOS ONE, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization SignalJournal of Biological Chemistry, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProceedings of the National Academy of Sciences, 2010
- Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patientsBritish Journal of Cancer, 2006
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003